Advanced Nanomaterials for the Diagnosis and Treatment of Renal Cell Carcinoma

被引:5
|
作者
Ji, Chen [1 ,2 ,3 ]
Li, Junru [1 ,2 ,3 ]
Mei, Junyang [1 ,2 ,3 ]
Su, Weiran [1 ,2 ,3 ]
Dai, Huili [1 ,2 ,3 ]
Li, Fengqin [1 ,2 ,3 ]
Liu, Peifeng [1 ,2 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, RenJi Hosp, Shanghai Canc Inst, Sch Med,State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Cent Lab, Shanghai 200127, Peoples R China
[3] Shanghai Jiao Tong Univ, RenJi Hosp, Micronano Res & Diag Ctr, Sch Med, Shanghai 200127, Peoples R China
来源
ADVANCED NANOBIOMED RESEARCH | 2023年 / 3卷 / 02期
基金
中国国家自然科学基金;
关键词
diagnosis; drug delivery systems; nanomaterials; renal cell carcinoma; treatments; MESOPOROUS SILICA NANOPARTICLES; IN-VITRO; DRUG-DELIVERY; IMMOBILIZED-TRYPSIN; CANCER; THERAPY; TUMOR; CONTRAST; SIRNA; BIODISTRIBUTION;
D O I
10.1002/anbr.202200079
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Renal cell carcinoma (RCC) is the most common type of kidney cancer. Owing to the high morbidity rate of RCC, there is an urgent need for intensive research on robust materials to diagnose and treat RCC. Nanomaterials have been developed largely in the last three decades because of their numerous advantages, such as high specific surface area, simple surface functionalization, rapid onset of therapeutic action, superior biological activity, and other unique physical-chemical characteristics. Herein, first, various types of nanomaterials used in RCC treatment are introduced, including inorganic nanomaterials, lipid nanomaterials, synthetic polymer nanomaterials, and natural nanomaterials. Second, the different diagnosis and therapeutic mechanisms of nanomaterials in the kidneys are reviewed and these advantages of nanomaterials are highlighted. Furthermore, nanomaterials are investigated for the preclinical and clinical detection and treatment of RCC. Finally, the challenges and outlook of various nanomaterials for RCC diagnostic and treatment are discussed.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Treatment of advanced renal cell carcinoma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2007, 49 (1276): : 103 - 104
  • [2] Treatment of Locally Advanced Renal Cell Carcinoma
    Huesch, Tanja
    Reiter, Michael A.
    Mager, Rene
    Kurosch, Martin
    Haferkamp, Axel
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (03) : 66 - 72
  • [3] Tivozanib for the treatment of advanced renal cell carcinoma
    Chatzkel, Jonathan
    Ramnaraign, Brian
    Sonpavde, Guru
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (10) : 1135 - 1142
  • [4] Temsirolimus in the treatment of advanced renal cell carcinoma
    Escudier, Bernard J.
    ONCOLOGY REVIEWS, 2007, 1 (02) : 73 - 80
  • [5] Pazopanib in the treatment of advanced renal cell carcinoma
    Cella, David
    Beaumont, Jennifer L.
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (01) : 61 - 69
  • [6] Treatment of Advanced Renal-Cell Carcinoma
    Huillard, Olivier
    Alexandre, Jerome
    Goldwasser, Francois
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (09): : 888 - 888
  • [7] Sorafenib for the treatment of advanced renal cell carcinoma
    Kane, Robert C.
    Farrell, Ann T.
    Saber, Haleh
    Tang, Shenghui
    Williams, Gene
    Jee, Josephine M.
    Liang, Chengyi
    Booth, Brian
    Chidambaram, Nallaperumal
    Morse, David
    Sridhara, Rajeshwari
    Garvey, Patricia
    Justice, Robert
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2006, 12 (24) : 7271 - 7278
  • [8] Treatment of advanced pediatric renal cell carcinoma
    Annbalavanan, Manoj
    Geller, James, I
    PEDIATRIC BLOOD & CANCER, 2019, 66 (08)
  • [9] Sunitinib in the treatment of advanced renal cell carcinoma
    Drab-Mazur, Iwona
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : A43 - A44
  • [10] Axitinib for the treatment of advanced renal cell carcinoma
    Akaza, Hideyuki
    Fukuyama, Tomofusa
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (02) : 283 - 297